Vitrolife AB (publ) (STO: VITR) Q2 2025 Earnings | 17/07/2025

About this video

Vitrolife AB (publ) (STO: VITR) Q2 2025 Earnings | 17/07/2025 Financial Highlights Net Sales: SEK 871 million (Q2 2024: SEK 941 million) Represented a 7% decline year-over-year in SEK, primarily due to an 8% negative currency effect In local currencies, sales were flat; organic growth excluding discontinued business was 3% Gross Margin: 58.0% (down from 59.9%) EBITDA: SEK 243 million, with margin of 27.8% (down from 34.7%) Net Income: SEK 100 million (Q2 2024: SEK 143 million) Earnings Per Share: SEK 0.74 (Q2 2024: SEK 1.06) Operating Cash Flow: SEK 151 million (Q2 2024: SEK 236 million) Segment & Regional Performance Consumables: Up 9% (organic, in local currencies, excluding discontinued business) Technologies: Down 6% Genetics: Up 3% (excluding discontinued business) Regional Summary: EMEA: -3% (or +5% excluding discontinued business) Americas: +5% APAC: 0% growth Strategic & Operational Updates Significant negative currency impacts affected both topline and margins, with SEK results down 7% despite neutral sales in local currencies. EBITDA margin contraction was mainly due to negative currency effects and a less favorable sales mix. Cash flow remained healthy, with a positive operating cash flow of SEK 151 million. Vitrolife completed the strategic acquisition of a majority stake in AutoIVF, reflecting continued investment in growth platforms. Management & Market Commentary Mixed Q2 results reflect the impact of currency volatility and ongoing challenges in some international markets, especially the U.S. IVF segment. The company remains focused on product innovation and expanding market access capabilities, particularly in the U.S. and core EMEA regions. Despite the reported EPS and revenue miss versus market expectations—which prompted a notable share price drop—management highlights the resilience of core business lines and the potential for margin recovery as currency pressures moderate. Outlook Vitrolife maintains its outlook for organic growth in local currencies, supported by strong consumables performance and innovation in Genetics. Management continues to prioritize operational efficiency, market adaptation, and margin stabilization going into the latter half of 2025. About Inside Ticker: For more expert analysis and real-time updates on Vitrolife AB (publ) (STO: VITR) and other market movers, follow Inside Ticker and visit InsideTicker.com for in-depth reports, financial insights, and the latest news on leading companies. #Vitrolife #VITR #Q22025 #Earnings #IVF #Consumables #FinancialResults #NetSales #GrossMargin #OrganicGrowth #StockMarket #InsideTicker #MedTech #Genetics #OperatingPerformance #BusinessUpdate #CurrencyImpact #Innovation #Sweden #2025Outlook